Zacks: Analysts Anticipate Trevena, Inc. (NASDAQ:TRVN) to Post -$0.31 EPS
Analysts expect Trevena, Inc. (NASDAQ:TRVN) to post earnings of ($0.31) per share for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Trevena’s earnings, with estimates ranging from ($0.37) to ($0.24). Trevena posted earnings per share of ($0.57) during the same quarter last year, which indicates a positive year over year growth rate of 45.6%. The firm is scheduled to announce its next quarterly earnings report on Thursday, November 2nd.
According to Zacks, analysts expect that Trevena will report full-year earnings of ($1.39) per share for the current fiscal year, with EPS estimates ranging from ($1.92) to ($1.14). For the next fiscal year, analysts forecast that the business will post earnings of ($0.94) per share, with EPS estimates ranging from ($1.17) to ($0.77). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that cover Trevena.
Trevena (NASDAQ:TRVN) last issued its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported ($0.35) EPS for the quarter, hitting the consensus estimate of ($0.35).
A number of research firms have commented on TRVN. Oppenheimer Holdings, Inc. set a $10.00 target price on Trevena and gave the company a “buy” rating in a report on Thursday, May 4th. Zacks Investment Research cut Trevena from a “hold” rating to a “sell” rating in a research report on Wednesday, July 26th. Needham & Company LLC restated a “buy” rating and issued a $9.00 price target (down previously from $11.00) on shares of Trevena in a research report on Friday, May 5th. HC Wainwright restated a “buy” rating on shares of Trevena in a research report on Monday, May 8th. Finally, Aegis restated a “buy” rating and issued a $14.00 price target on shares of Trevena in a research report on Monday, April 17th. One research analyst has rated the stock with a sell rating and twelve have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $10.56.
Shares of Trevena (NASDAQ TRVN) traded down 2.45% during midday trading on Wednesday, reaching $2.39. 300,248 shares of the company traded hands. The stock’s market capitalization is $139.34 million. The stock’s 50-day moving average is $2.56 and its 200-day moving average is $3.77. Trevena has a 1-year low of $2.15 and a 1-year high of $8.00.
A number of hedge funds have recently bought and sold shares of the company. American International Group Inc. boosted its stake in Trevena by 7.1% in the first quarter. American International Group Inc. now owns 27,541 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 1,816 shares in the last quarter. Bourgeon Capital Management LLC boosted its stake in Trevena by 56.8% in the second quarter. Bourgeon Capital Management LLC now owns 53,031 shares of the biopharmaceutical company’s stock worth $122,000 after buying an additional 19,200 shares in the last quarter. Daiwa SB Investments Ltd. bought a new stake in Trevena during the first quarter worth approximately $126,000. SG Americas Securities LLC boosted its stake in Trevena by 81.0% in the first quarter. SG Americas Securities LLC now owns 35,926 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 16,079 shares in the last quarter. Finally, Rhumbline Advisers boosted its stake in Trevena by 30.1% in the second quarter. Rhumbline Advisers now owns 64,251 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 14,880 shares in the last quarter. Hedge funds and other institutional investors own 64.40% of the company’s stock.
Trevena Company Profile
Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.